Filing Details
- Accession Number:
- 0001562180-18-004984
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-17 16:27:56
- Reporting Period:
- 2018-12-17
- Accepted Time:
- 2018-12-17 16:27:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1560241 | G1 Therapeutics Inc. | GTHX | Pharmaceutical Preparations (2834) | 263648180 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706853 | Rajesh Malik | C/O G1 Therapeutics, 79 Tw Alexander Dr. 4501 Research Commons, Suite 100 Research Triangle Park NC 27709 | Ch. Medical Officer & Svp R&D | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-12-17 | 3,776 | $4.17 | 18,476 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-12-17 | 3,776 | $30.00 | 14,700 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2018-12-17 | 3,776 | $0.00 | 3,776 | $4.17 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 65,519 | 2026-05-10 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- The shares underlying this option vested as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Billionaire Hedge Funds
